Furthermore, BCL-xL inhibition significantly reduced the tumor burden in a mouse xenograft model, suggesting that targeting BCL-xL could offer a promising therapeutic strategy for erythroid/megakaryoblastic leukemias and highlighting a subgroup of AML with reduced sensitivity to VEN-based treatments [77]. The gene discussed is BCL2L1; the disease is neoplasm.